Log In
BCIQ
Print this Print this
 

DT2219ARL (OXS-1550)

  Manage Alerts
Collapse Summary General Information
Company Oxis International Inc.
DescriptionBispecific single-chain variable fragment (scFv) recombinant fusion antibody-drug conjugate comprising the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified diphtheria toxin payload
Molecular Target CD19 ; CD22
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationB cell lymphoma
Indication DetailsTreat CD19-positive and/or CD22-positive B cell malignancies
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/08/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today